Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Khalid A Mohamedali

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Biomedicines|July 18, 2017
Targeting of Tumor Neovasculature with GrB/VEGF<sub>121</sub>, a Novel Cytotoxic Fusion ProteinKhalid A Mohamedali, Michael G Rosenblum
Journal of Biotechnology|January 16, 2007
Overexpression of biologically active VEGF121 fusion proteins in Escherichia coliSehoon Kim, Khalid A Mohamedali, Lawrence H Cheung, et al.
Methods in Enzymology|January 3, 2012
Cell-targeting fusion constructs containing recombinant geloninMi-Ae Lyu, Yu Joshua Cao, Khalid A Mohamedali, et al.
Neoplasia (New York, N.Y.)|June 22, 2005
The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumorsSophia Ran, Khalid A Mohamedali, Troy A Luster, et al.
Molecular Cancer Therapeutics|July 17, 2013
The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growthKhalid A Mohamedali, Yu Cao, Lawrence H Cheung, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 2, 2006
PET of vascular endothelial growth factor receptor expressionWeibo Cai, Kai Chen, Khalid A Mohamedali, et al.
Molecular Cancer Therapeutics|March 16, 2013
Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neuYu Cao, Khalid A Mohamedali, John W Marks, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 18, 2014
Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxinAnette Weyergang, Lawrence H Cheung, Michael G Rosenblum, et al.
Biochemical Pharmacology|October 2, 2012
Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGelKhalid A Mohamedali, Gang Niu, Troy A Luster, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 1, 2019
Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme BLawrence H Cheung, Yunli Zhao, Ana Alvarez-Cienfuegos, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Biomedicines|July 18, 2017
Targeting of Tumor Neovasculature with GrB/VEGF<sub>121</sub>, a Novel Cytotoxic Fusion ProteinKhalid A Mohamedali, Michael G Rosenblum
Journal of Biotechnology|January 16, 2007
Overexpression of biologically active VEGF121 fusion proteins in Escherichia coliSehoon Kim, Khalid A Mohamedali, Lawrence H Cheung, et al.
Methods in Enzymology|January 3, 2012
Cell-targeting fusion constructs containing recombinant geloninMi-Ae Lyu, Yu Joshua Cao, Khalid A Mohamedali, et al.
Neoplasia (New York, N.Y.)|June 22, 2005
The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumorsSophia Ran, Khalid A Mohamedali, Troy A Luster, et al.
Molecular Cancer Therapeutics|July 17, 2013
The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growthKhalid A Mohamedali, Yu Cao, Lawrence H Cheung, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 2, 2006
PET of vascular endothelial growth factor receptor expressionWeibo Cai, Kai Chen, Khalid A Mohamedali, et al.
Molecular Cancer Therapeutics|March 16, 2013
Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neuYu Cao, Khalid A Mohamedali, John W Marks, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 18, 2014
Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxinAnette Weyergang, Lawrence H Cheung, Michael G Rosenblum, et al.
Biochemical Pharmacology|October 2, 2012
Pharmacodynamics, tissue distribution, toxicity studies and antitumor efficacy of the vascular targeting fusion toxin VEGF121/rGelKhalid A Mohamedali, Gang Niu, Troy A Luster, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 1, 2019
Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme BLawrence H Cheung, Yunli Zhao, Ana Alvarez-Cienfuegos, et al.
Pageof 3